ClinicalTrials.gg
CompletedNCT02919475MOVE-RAUpdated Jun 14, 2021Results posted

Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis

A Phase 2 interventional study of JTE-051 and Placebo in Rheumatoid Arthritis, sponsored by Akros Pharma Inc.. Completed at 39 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Akros Pharma Inc. (part of Shionogi) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 118 studies in Arthritis, Rheumatoid with a site in Ukraine — 4 open to participants now, 8 under way, 1 of them phase 3. Arthritis, Rheumatoid · Ukraine.

Enrollment
80th of 115
260 · median 409
Started
2016
with 9 others
Phase 2
56 of 118
1 open now
Registered
94th of 118
by date

Among the 118 studies in Arthritis, Rheumatoid with a site in Ukraine, this one is the 80th largest by enrollment of the 115 interventional ones that give a count, is one of 10 that started in 2016, is one of 56 in phase 2, and was the 94th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 118 studies in Arthritis, Rheumatoid with a site in Ukraine are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Arthritis, Rheumatoid with a site in Ukraine, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of JTE-051 administered for 12 weeks in subjects with active rheumatoid arthritis who are receiving background non-biologic disease-modifying anti-rheumatic drug therapy.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • JTE-051
  • Active Rheumatoid Arthritis
  • Efficacy
  • Safety
  • Tolerability
  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of RA prior to the Screening Visit.
  • Active disease despite ongoing therapy with up to two non-biologic disease-modifying anti-rheumatic drugs, including methotrexate at both the Screening and Baseline Visits.
  • Screening hs-CRP ≥1.2 x (ULN).

Exclusion criteria

Exclusion Criteria:

  • Prior/current exposure to biologic and/or kinase inhibitor therapy.
  • Known history or presence of polyneuropathy of any cause and no presence of clinically active compression neuropathy, radiculopathy or plexopathy at the Screening Visit.
  • Positive test results for human immunodeficiency () virus, virus or (HCV) virus at the Screening Visit.
  • Positive drug of abuse and alcohol test results.
  • History of a clinically-significant infection that required oral antimicrobial or antiviral therapy within 8 weeks prior to Day 1.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    JTE-051 Dose 1

    One dose of study drug by mouth daily for 12 weeks

    Drug: JTE-051

  • Experimental
    JTE-051 Dose 2

    One dose of study drug by mouth daily for 12 weeks

    Drug: JTE-051

  • Experimental
    JTE-051 Dose 3

    One dose of study drug by mouth daily for 12 weeks

    Drug: JTE-051

  • Experimental
    JTE-051 Dose 4

    One dose of study drug by mouth daily for 12 weeks

    Drug: JTE-051

  • Experimental
    Placebo

    One dose of study drug by mouth daily for 12 weeks

    Drug: Placebo

Interventions

  • DrugJTE-051

    Active drug tablets containing JTE-051

  • DrugPlacebo

    Placebo tablets identical in appearance to the active drug tablets

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Achieving at Least 20% Improvement From Baseline in American College of Rheumatology (ACR) Core Set Measures (ACR20 Response Rate) Compared to Placebo at End-of-treatment (EOT)

    Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at EOT (up to Week 12) compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)

    Time frame: Up to 12 Weeks

Secondary outcomes

  1. Percentage of Subjects Achieving ACR20 Response Rate Compared to Placebo at Week 12

    Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)

    Time frame: Week 12

  2. Percentage of Subjects Achieving ACR50 Response Rate Compared to Placebo at Week 12

    Percentage of subjects achieving at least 50% improvement from baseline (ACR50) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 50% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)

    Time frame: Week 12

  3. Percentage of Subjects Achieving ACR70 Response Rate Compared to Placebo at Week 12

    Percentage of subjects achieving at least 70% improvement from baseline (ACR70) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 70% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)

    Time frame: Week 12

  4. Change From Baseline in SDAI (Simplified Disease Activity Index) at Week 12

    The SDAI Scores indicate how active a patient's rheumatoid arthritis (RA) is currently. The SDAI is the sum of 5 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10), Physician's Global Score of disease activity (0 to 10) and C-reactive protein (CRP, 0 to 10).General SDAI Score Interpretation is as follows: 0.0 - 3.3 Remission 3.4 - 11.0 Low Activity 11.1 - 26.0 Moderate Activity 26.1 - 86.0 High Activity

    Time frame: Week 12

  5. Change From Baseline in CDAI (Clinical Disease Activity Index) at Week 12

    The CDAI is a useful clinical composite score for following patients with rheumatoid arthritis (RA). The CDAI is the sum of 4 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10) and Physician's Global Score of disease activity (0 to 10). The CDAI Score Interpretation is as follows: 0 to 2.8: Remission 2.9 to 10: Low Disease Activity 10.1 to 22: Moderate Disease Activity 22.1 to 76: High Disease Activity

    Time frame: Week 12

  6. Change From Baseline in DAS28-CRP (Disease Activity Score [DAS] Based on High-sensitivity C-reactive Protein [Hs-CRP]) at Week 12

    Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consists of composite score of following variables: 28 tender joint count (TJC28) ranging from 0 to 28, 28 swollen joint count (SJC28) ranged from 0 to 28, C-reactive protein (CRP) (milligrams per liter) and subject's global assessment of disease activity (SGA) ranging from 0 (no disease activity) to 10 (extremely active disease). DAS28-CRP was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*SGA+0.96. DAS28-CRP ranged from 0.96-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

    Time frame: Week 12

  7. Change From Baseline in HAQ-DI (Health Assessment Questionnaire Disability Index) at Week 12

    The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] in 8 functional area categories: (1) dressing and grooming; (2) arising; (3) eating; (4) walking; (5) hygiene; (6) reaching; (7) gripping; and (8) performing other daily activities. Scores from each functional area category (total 8 categories) were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

    Time frame: Week 12

  8. Number of Subjects With Treatment-related Adverse Events

    Subjects in the Safety Population (258, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The number of subjects in the Safety Population is 258 subjects, which is 1 less than the Randomized Population of 259 subjects, since 1 randomized subject did not receive any study drug.

    Time frame: Up to 16 Weeks

  9. Trough Concentrations (Ctrough) of JTE-051 in Plasma at Week 12

    Time frame: Week 12

07

Results

Posted Jun 14, 2021
Limitations and caveats
None reported.

Participant flow

Written informed consent was obtained prior to performing any study-related procedures. A copy of the informed consent was provided to each subject enrolled in this study. To qualify for the study, subjects were required to satisfy defined criteria.

Participant flow — Overall Study
MilestoneJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Started5252525152
Started dosing5152525152
Completed4644473848
Not completed685134
Withdrew: Adverse event33392
Withdrew: Death01000
Withdrew: Lost to follow-up00010
Withdrew: Withdrawal by subject23122
Withdrew: Inclusion/exclusion criteria not met11110

Outcome measures

PrimaryPercentage of Subjects Achieving at Least 20% Improvement From Baseline in American College of Rheumatology (ACR) Core Set Measures (ACR20 Response Rate) Compared to Placebo at End-of-treatment (EOT)

Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at EOT (up to Week 12) compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)

Time frame:
Up to 12 Weeks
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving at Least 20% Improvement From Baseline in American College of Rheumatology (ACR) Core Set Measures (ACR20 Response Rate) Compared to Placebo at End-of-treatment (EOT)
ParticipantsJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Percentage of Subjects Achieving at Least 20% Improvement From Baseline in American College of Rheumatology (ACR) Core Set Measures (ACR20 Response Rate) Compared to Placebo at End-of-treatment (EOT)2731273029
Statistical analysis
  • JTE-051 50 mg vs Placebo · Fisher Exact · p = 0.842
  • JTE-051 100 mg vs Placebo · Fisher Exact · p = 0.841
  • JTE-051 150 mg vs Placebo · Fisher Exact · p = 0.842
  • JTE-051 200 mg vs Placebo · Fisher Exact · p = >0.999
SecondaryPercentage of Subjects Achieving ACR20 Response Rate Compared to Placebo at Week 12

Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving ACR20 Response Rate Compared to Placebo at Week 12
ParticipantsJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Percentage of Subjects Achieving ACR20 Response Rate Compared to Placebo at Week 122628252428
Statistical analysis
  • JTE-051 50 mg vs Placebo · Fisher Exact · p = >0.999
  • JTE-051 100 mg vs Placebo · Fisher Exact · p = 0.832
  • JTE-051 150 mg vs Placebo · Fisher Exact · p = 0.682
  • JTE-051 200 mg vs Placebo · Fisher Exact · p = 0.665
SecondaryPercentage of Subjects Achieving ACR50 Response Rate Compared to Placebo at Week 12

Percentage of subjects achieving at least 50% improvement from baseline (ACR50) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 50% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving ACR50 Response Rate Compared to Placebo at Week 12
ParticipantsJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Percentage of Subjects Achieving ACR50 Response Rate Compared to Placebo at Week 12101281110
Statistical analysis
  • JTE-051 50 mg vs Placebo · Fisher Exact · p = >0.999
  • JTE-051 100 mg vs Placebo · Fisher Exact · p = 0.627
  • JTE-051 150 mg vs Placebo · Fisher Exact · p = 0.794
  • JTE-051 200 mg vs Placebo · Fisher Exact · p = 0.453
SecondaryPercentage of Subjects Achieving ACR70 Response Rate Compared to Placebo at Week 12

Percentage of subjects achieving at least 70% improvement from baseline (ACR70) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 70% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving ACR70 Response Rate Compared to Placebo at Week 12
ParticipantsJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Percentage of Subjects Achieving ACR70 Response Rate Compared to Placebo at Week 1235440
Statistical analysis
  • JTE-051 50 mg vs Placebo · Fisher Exact · p = 0.113
  • JTE-051 100 mg vs Placebo · Fisher Exact · p = 0.024
  • JTE-051 150 mg vs Placebo · Fisher Exact · p = 0.056
  • JTE-051 200 mg vs Placebo · Fisher Exact · p = 0.035
SecondaryChange From Baseline in SDAI (Simplified Disease Activity Index) at Week 12

The SDAI Scores indicate how active a patient's rheumatoid arthritis (RA) is currently. The SDAI is the sum of 5 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10), Physician's Global Score of disease activity (0 to 10) and C-reactive protein (CRP, 0 to 10).General SDAI Score Interpretation is as follows: 0.0 - 3.3 Remission 3.4 - 11.0 Low Activity 11.1 - 26.0 Moderate Activity 26.1 - 86.0 High Activity

Time frame:
Week 12
Reported as:
Mean · Score on a scale
Change From Baseline in SDAI (Simplified Disease Activity Index) at Week 12
Score on a scaleJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Change From Baseline in SDAI (Simplified Disease Activity Index) at Week 12-18.14 ± 15.437-21.68 ± 13.275-19.41 ± 16.446-19.97 ± 14.244-17.66 ± 16.816
SecondaryChange From Baseline in CDAI (Clinical Disease Activity Index) at Week 12

The CDAI is a useful clinical composite score for following patients with rheumatoid arthritis (RA). The CDAI is the sum of 4 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10) and Physician's Global Score of disease activity (0 to 10). The CDAI Score Interpretation is as follows: 0 to 2.8: Remission 2.9 to 10: Low Disease Activity 10.1 to 22: Moderate Disease Activity 22.1 to 76: High Disease Activity

Time frame:
Week 12
Reported as:
Mean · Score on a scale
Change From Baseline in CDAI (Clinical Disease Activity Index) at Week 12
Score on a scaleJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Change From Baseline in CDAI (Clinical Disease Activity Index) at Week 12-18.76 ± 14.768-22.40 ± 13.469-21.02 ± 16.153-21.24 ± 14.208-17.19 ± 15.548
SecondaryChange From Baseline in DAS28-CRP (Disease Activity Score [DAS] Based on High-sensitivity C-reactive Protein [Hs-CRP]) at Week 12

Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consists of composite score of following variables: 28 tender joint count (TJC28) ranging from 0 to 28, 28 swollen joint count (SJC28) ranged from 0 to 28, C-reactive protein (CRP) (milligrams per liter) and subject's global assessment of disease activity (SGA) ranging from 0 (no disease activity) to 10 (extremely active disease). DAS28-CRP was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*SGA+0.96. DAS28-CRP ranged from 0.96-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

Time frame:
Week 12
Reported as:
Mean · Score on a scale
Change From Baseline in DAS28-CRP (Disease Activity Score [DAS] Based on High-sensitivity C-reactive Protein [Hs-CRP]) at Week 12
Score on a scaleJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Change From Baseline in DAS28-CRP (Disease Activity Score [DAS] Based on High-sensitivity C-reactive Protein [Hs-CRP]) at Week 12-0.95 ± 1.039-1.23 ± 0.979-1.03 ± 1.123-1.10 ± 0.987-0.98 ± 1.123
SecondaryChange From Baseline in HAQ-DI (Health Assessment Questionnaire Disability Index) at Week 12

The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] in 8 functional area categories: (1) dressing and grooming; (2) arising; (3) eating; (4) walking; (5) hygiene; (6) reaching; (7) gripping; and (8) performing other daily activities. Scores from each functional area category (total 8 categories) were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

Time frame:
Week 12
Reported as:
Mean · Score on a scale
Change From Baseline in HAQ-DI (Health Assessment Questionnaire Disability Index) at Week 12
Score on a scaleJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Change From Baseline in HAQ-DI (Health Assessment Questionnaire Disability Index) at Week 12-0.52 ± 0.600-0.71 ± 0.629-0.60 ± 0.620-0.80 ± 0.727-0.47 ± 0.616
SecondaryNumber of Subjects With Treatment-related Adverse Events

Subjects in the Safety Population (258, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The number of subjects in the Safety Population is 258 subjects, which is 1 less than the Randomized Population of 259 subjects, since 1 randomized subject did not receive any study drug.

Time frame:
Up to 16 Weeks
Reported as:
Count of participants · Participants
Number of Subjects With Treatment-related Adverse Events
ParticipantsJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Number of subjects with TEAEs2621323422
Number of subjects with no TEAEs2531201730
SecondaryTrough Concentrations (Ctrough) of JTE-051 in Plasma at Week 12
Time frame:
Week 12
Reported as:
Mean · ng/mL
Trough Concentrations (Ctrough) of JTE-051 in Plasma at Week 12
ng/mLJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mg
Trough Concentrations (Ctrough) of JTE-051 in Plasma at Week 12119 ± 96.9178 ± 156312 ± 252354 ± 281

Adverse events

Collected over Up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
JTE-051 50 mg0/51 (0%)2/51 (3.9%)11/51 (21.6%)
JTE-051 100 mg1/52 (1.9%)3/52 (5.8%)7/52 (13.5%)
JTE-051 150 mg0/52 (0%)2/52 (3.8%)20/52 (38.5%)
JTE-051 200 mg0/51 (0%)1/51 (2%)21/51 (41.2%)
Placebo0/52 (0%)0/52 (0%)3/52 (5.8%)
Most frequent serious events
Most frequent serious events
EventJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
AppendicitisInfections and infestations1/510/520/520/510/52
Cellulitis/Cellulitis in right handInfections and infestations1/510/520/520/510/52
UrticariaSkin and subcutaneous tissue disorders0/510/520/521/510/52
Abdominal pain/Diffused abdominal painGastrointestinal disorders0/511/520/520/510/52
Gastric ulcerGastrointestinal disorders0/510/521/520/510/52
Pneumonia/Bilateral pneumoniaInfections and infestations0/511/520/520/510/52
Rheumatoid arthritis/Exacerbation of rheumatoid arthritisMusculoskeletal and connective tissue disorders0/510/521/520/510/52
Insomnia/Sleep Disorders: InsomniaPsychiatric disorders0/511/520/520/510/52
Most frequent other events
Most frequent other events
EventJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
DysgeusiaNervous system disorders2/511/522/529/510/52
Urinary tract infectionInfections and infestations3/513/525/528/512/52
ConstipationGastrointestinal disorders3/511/526/522/510/52
NasopharyngitisInfections and infestations2/511/524/520/510/52
AnemiaBlood and lymphatic system disorders1/511/523/522/511/52

Baseline characteristics

Baseline characteristics results are reported for the Intent-to-Treat (ITT) population: 257 subjects who received at least one dose of JTE-051 or placebo and had at least one post-baseline efficacy assessment during the double-blind treatment period.

Age, Categorical
Age, Categorical(Participants)JTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlaceboTotal
<=18 years000000
Between 18 and 65 years4248464344223
>=65 years9368834
Sex: Female, Male
Sex: Female, Male(Participants)JTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlaceboTotal
Female4140444343211
Male101188946
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)JTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlaceboTotal
Hispanic or Latino2727262726133
Not Hispanic or Latino2424262426124
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)JTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlaceboTotal
American Indian or Alaska Native8867332
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White3134313433163
More than one race12915101662
Unknown or Not Reported000000
08

Study locations

39 sites
  • Tucson, Arizona, United States
  • Upland, California, United States
  • Clearwater, Florida, United States
  • Hendersonville, Tennessee, United States
  • La Plata, Buenos Aires, Argentina
  • San Fernando, Buenos Aires, Argentina
  • Barrio Norte, Córdoba, Argentina
  • San Miguel De Tucumán, Tucumán, Argentina
  • Córdoba, Argentina
  • San Juan, Argentina
  • Lom, Bulgaria
  • Plovdiv, Bulgaria
  • Sevlievo, Bulgaria
  • Sofia, Bulgaria
  • Medellín, Antioquia, Colombia
  • Bogotá, Cundinamarca, Colombia
  • Cali, Valle Del Cauca, Colombia
  • Mexicali, B.c., Mexico
  • Guadalajara, Jalisco, Mexico
  • Mexico, Mexico City, Mexico
  • San Luis Potosí, SLP, Mexico
  • Mérida, Yucatan, Mexico
  • Lima, Peru
  • Warszawa, Masovian, Poland
  • Białystok, Podlaskie, Poland
  • Elbląg, Poland
  • Bucharest, Romania
  • Iaşi, Romania
  • Târgu-Mureş, Romania
  • Kazan, Russian Federation
  • Moscow, Russian Federation
  • Saint Petersburg, Russian Federation
  • Kharkiv, Ukraine
  • Kherson, Ukraine
  • Kyiv, Ukraine
  • Lviv, Ukraine
  • Sumy, Ukraine
  • Vinnytsia, Ukraine
  • Zaporizhzhia, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Jun 2018, 21 months.

Results were first posted in Jun 2021, 2 years 11 months after primary completion. A results delay was requested in Nov 2019.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 21 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2016
First posted
Sep 29, 2016
StartActual
Sep 14, 2016
Primary completionActual
Jun 25, 2018
CompletionActual
Jun 25, 2018
Results delay requested
Nov 6, 2019
Results first posted
Jun 14, 2021
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02919475
Lead sponsor
Akros Pharma Inc.
Responsible party
Sponsor
First posted
Sep 29, 2016
Start date
Sep 14, 2016
Primary completion
Jun 25, 2018
Completion
Jun 25, 2018
Results posted
Jun 14, 2021
Last update
Jun 14, 2021

Study contacts

Yoshiro Masuda
study chair · Akros Pharma Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion